Dyne issued a press release on September 3, 2024, “announc[ing] new clinical data from its ongoing Phase 1/2 DELIVER trial of DYNE-251 in patients with Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping demonstrating unprecedented dystrophin expression and functional improvement in multiple cohorts.” However, in a separate press release on that same day, Dyne announced that the Company’s chief medical officer, chief operating officer, and chief business officer were “step[ping] down from their roles”.

Following this news, Dyne’s stock price fell over 30% on September 3, 2024.